FDA OKs Mesenchymal Stromal Cell Therapy for GVHD ...Middle East

Medscape - News
Remestemcel-L (Ryoncil) is an allogeneic bone marrow‒derived mesenchymal stromal cell therapy for steroid-refractory acute graft-vs-host disease in pediatric patients as young as 2 months. Medscape Medical News

Hence then, the article about fda oks mesenchymal stromal cell therapy for gvhd was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA OKs Mesenchymal Stromal Cell Therapy for GVHD )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News